GEN News Highlights: Nov 10, 2011

Bruker and Berkeley Lab Combine NMR with SAXS for Analyzing Large Protein Complexes

(Page 1 of 1)

    Bruker and Lawrence Berkeley National Laboratory  are collaborating to develop structural biology methods and tools that integrate small-angle x-ray scattering (SAXS) technology with nuclear magnetic resonance (NMR). The aim is to generate a set of data analysis algorithms for determining the structures of larger, multidomain proteins and protein complexes with DNA, RNA, or other proteins.

    The organizations claim that combining the NMR-derived 3-D atomic structure of protein domains with calculations of overall size, shape, and envelope constrains provided by SAXS will enable more accurate analysis under near-native solution conditions.

    The organizations point out that while one of the benefits of NMR is that the technology can be used to study proteins in solution—providing information on different regions and domains, protein flexibility, partial folding, and unstructured regions—it can only work with molecules of up to 50–70 kDa. Moreover, they continue, even with the most advanced techniques and associated hardware and probes, solution NMR often lacks the ability to determine the exact global structure of larger molecular assemblies or multidomain proteins.

    Combining NMR data will SAXS is expected to compensate incomplete NMR datasets of biological molecules. Previous  studies have already shown that SAXS can effectively improve the quality and accuracy of NMR structures and also potentially extend the capability of NMR to larger molecules, Bruker and the Berkeley Lab state. In addition, SAXS represents a relatively fast, economical, and straightforward technique that doesn’t require complicated sample preparation and uses only a few micrograms of unlabeled, native protein in a monodisperse solution.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll